0001628280-26-031032
SEC filingStrong operational turnaround: revenue growth accelerated, operating losses narrowed sharply, and the company returned to profitability, driven by organ transplant volume growth and logistics expansion.
Revenue for the three months ended March 31, 2026 increased 24.1% to $67.4 million compared to $54.3 million in the prior year period. The growth was primarily driven by higher organ transplant volumes and expansion of our logistics services. As noted in our business context, the majority of our business is directly tied to the volume of heart, liver, and lung transplants performed in the United States, which is driven by the supply of donor organs. Our ability to aggregate demand across transplant centers and cardiac care hospitals has enabled us to optimize our staffing model and offer competitive pricing.
Net income was $2.2 million, or $0.03 per diluted share, compared to a net loss of -$3.5 million, or -$0.04 per diluted share, in the prior year. The swing to profitability was aided by non-operating income, which is not separately disclosed in the authoritative packet but is implied by the difference between operating loss and net income.